<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30517261</article-id><article-id pub-id-type="pmc">6257535</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0194</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Updated Meta-analysis on the Closure of Patent Foramen Ovale in
Reduction of Stroke Rates: the DEFENSE-PFO Trial Does not Change the
Scenario</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>S&#x000e1;</surname><given-names>Michel Pompeu Barros Oliveira</given-names></name><role>MD, MSc, PhD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Vieira</surname><given-names>Erik Everton Silva</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cavalcanti</surname><given-names>Luiz Rafael Pereira</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Diniz</surname><given-names>Roberto Gouveia Silva</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rayol</surname><given-names>S&#x000e9;rgio da Costa</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>de Menezes</surname><given-names>Alexandre Motta</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lins</surname><given-names>Ricardo Felipe de Albuquerque</given-names></name><role>MD</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Ricardo Carvalho</given-names></name><role>MD, MSc, PhD, ChM, AATS</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery of the Pronto Socorro
Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Recife, PE, Brazil.</aff><aff id="aff2">
<label>2</label> Universidade de Pernambuco (UPE), Recife, PE, Brazil.</aff><aff id="aff3">
<label>3</label> Nucleus of Postgraduate Studies and Research in Health Sciences of
the Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas and Instituto de Ci&#x000ea;ncias
Biol&#x000f3;gicas (FCM/ICB), Recife, PE, Brazil.</aff><aff id="aff4">
<label>4</label> The CASUAL Investigators &#x02013; CArdiovascular SUgery Academic League of
the Universidade de Pernambuco (UPE), Recife, PE, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: Michel Pompeu Barros Oliveira S&#x000e1;,
Pronto-Socorro Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Rua dos Palmares S/N
&#x02013; Santo Amaro &#x02013; Recife, PE, Brazil &#x02013; Zip code: 74970-240. E-mail:
<email>michel_pompeu@yahoo.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2018</year></pub-date><volume>33</volume><issue>5</issue><fpage>511</fpage><lpage>521</lpage><history><date date-type="received"><day>27</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>We aimed to analyze whether patent foramen ovale (PFO) closure reduces the
risk of stroke, assessing also some safety outcomes after the publication of
a new trial.</p></sec><sec><title>Introduction</title><p>The clinical benefit of closing a PFO has been an open question, so it is
necessary to review the current state of published medical data in regards
to this subject.</p></sec><sec><title>Methods</title><p>MEDLINE, EMBASE, CENTRAL/CCTR, SciELO, LILACS, Google Scholar and reference
lists of relevant articles were used to search for randomized controlled
trials (RCTs) that reported any of the following outcomes: stroke, death,
major bleeding or atrial fibrillation. Six studies fulfilled our eligibility
criteria and included 3560 patients (1889 for PFO closure and 1671 for
medical therapy.</p></sec><sec><title>Results</title><p>The risk ration (RR) for stroke in the &#x0201c;closure&#x0201d; group compared with the
&#x0201c;medical therapy&#x0201d; showed a statistically significant difference between the
groups, favouring the &#x0201c;closure&#x0201d; group (RR 0.366; 95%CI 0.171&#x02013;0.782,
<italic>P</italic>=0.010). There was no statistically significant
difference between the groups regarding the safety outcomes, death and major
bleeding, but we observed an increase in the risk of atrial fibrillation in
the &#x0201c;closure&#x0201d; group (RR 4.131; 95%CI 2.293&#x02013;7.443,
<italic>P</italic>&#x0003c;0.001). We also observed that the larger the
proportion of effective closure, the lower the risk of stroke.</p></sec><sec><title>Conclusion</title><p>This meta-analysis found that stroke rates are lower with percutaneously
implanted device closure than with medical therapy alone, being these rates
modulated by the rates of hypertension, atrial septal aneurysm and effective
closure. The publication of a new trial did not change the scenario in the
medical literature.</p></sec></abstract><kwd-group><kwd>Foramen Ovale, Patent</kwd><kwd>Vascular Closure Devices</kwd><kwd>Meta-analysis</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AHA</td><td align="left" rowspan="1" colspan="1">= American Heart Association</td></tr><tr><td align="left" rowspan="1" colspan="1">ASA</td><td align="left" rowspan="1" colspan="1">= American Stroke Association</td></tr><tr><td align="left" rowspan="1" colspan="1">CI</td><td align="left" rowspan="1" colspan="1">= Confidence interval</td></tr><tr><td align="left" rowspan="1" colspan="1">PFO</td><td align="left" rowspan="1" colspan="1">= Patent foramen ovale</td></tr><tr><td align="left" rowspan="1" colspan="1">PICOS</td><td align="left" rowspan="1" colspan="1">= Population, Intervention, Comparison, Outcome and Study
design</td></tr><tr><td align="left" rowspan="1" colspan="1">PRISMA</td><td align="left" rowspan="1" colspan="1">= Preferred Reporting Items for Systematic Reviews and
Meta-Analyses</td></tr><tr><td align="left" rowspan="1" colspan="1">RCTs</td><td align="left" rowspan="1" colspan="1">= Randomized controlled trials</td></tr><tr><td align="left" rowspan="1" colspan="1">RR</td><td align="left" rowspan="1" colspan="1">= Risk ration</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><sec><title>Rationale</title><p>Current American Heart Association;American Stroke Association (AHA;ASA)
guidelines do not support the use of patent foramen ovale (PFO) closure among
patients with PFO and cryptogenic stroke<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. However, new meta-analysis of randomized controlled
trials (RTCs)with the same number of patients and studies were
published<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r12" ref-type="bibr">12</xref>]</sup> this year, all of them coming
to the same conclusion: stroke rates are lower with percutaneously implanted
device closure than with medical therapy alone. As we know, the medical
literature currently changes at a fast pace. No sooner had all these
meta-analyses been published than a new trial (DEFENSE-PFO) came out. Therefore,
it is necessary to constantly review the current published medical data with
regard to this subject.</p></sec><sec><title>Objective</title><p>We aimed to analyze whether PFO closure reduces the risk of stroke, assessing
also some safety outcomes. This analysis was planned in accordance with current
guidelines for performing comprehensive systematic reviews and meta-analysis
with meta-regression, including the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA)<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> guidelines for RCTs. We pre-specified our analytical
plan and registered the study protocol with PROSPERO, the international
prospective register of systematic reviews (CRD42018084583).</p></sec></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Eligibility Criteria</title><p>With the Population, Intervention, Comparison, Outcome and Study desing (PICOS)
strategy, studies were only considered if: 1) the population comprised patients
with recent stroke or transient ischemic attack who had a PFO; 2) there was an
intervention group of device closure; 3) there was a control group receiving
medical therapy; 4) studied outcomes included any of the following: stroke,
death, major bleeding, atrial fibrillation; 5) studies were RCTs.</p></sec><sec><title>Information Sources</title><p>The following databases were used (until April 2018): MEDLINE; EMBASE;
CENTRAL/CCTR (Cochrane Controlled Trials Register); ClinicalTrials.gov; SciELO
(Scientific Electronic Library Online); LILACS (Literatura Latino Americana em
Ci&#x000ea;ncias da Sa&#x000fa;de); Google Scholar; and reference lists of
relevant articles.</p></sec><sec><title>Search</title><p>We conducted the research with Medical Subject Headings (MeSH) terms (&#x02018;Foramen
Ovale, Patent' OR &#x02018;Patent Oval Foramen &#x02018; OR &#x02018;Oval Foramen, Patent' OR &#x02018;Patent
Foramen Ovale') AND (&#x02018;Stroke' OR &#x02018;Cerebrovascular Accident' OR &#x02018;Cerebrovascular
Accidents' OR &#x02018;CVA' OR &#x02018;CVAs' OR &#x02018;Cerebrovascular Apoplexy' OR &#x02018;Apoplexy,
Cerebrovascular' OR &#x02018;Vascular Accident, Brain' OR &#x02018;Brain Vascular Accident &#x02018; OR
&#x02018;Brain Vascular Accidents' OR &#x02018;Vascular Accidents, Brain &#x02018; OR &#x02018;Cerebrovascular
Stroke' OR &#x02018;Cerebrovascular Strokes' OR &#x02018;Stroke, Cerebrovascular' OR &#x02018;Strokes,
Cerebrovascular' OR &#x02018;Apoplexy &#x02018; OR &#x02018;Cerebral Stroke' OR &#x02018;Cerebral Strokes' OR
&#x02018;Stroke, Cerebral' OR &#x02018;Strokes, Cerebral' OR &#x02018;Stroke, Acute' OR &#x02018;Acute Stroke'
OR &#x02018;Acute Strokes' OR &#x02018;Strokes, Acute' OR &#x02018;Cerebrovascular Accident, Acute' OR
&#x02018;Acute Cerebrovascular Accident' OR &#x02018;Acute Cerebrovascular Accidents' OR
&#x02018;Cerebrovascular Accidents, Acute').</p></sec><sec><title>Study Selection</title><p>The following steps were taken: 1) identification of titles of records through
database research; 2) removal of duplicates; 3) screening and selection of
abstracts; 4) assessment for eligibility through full-text articles; and 5)
final inclusion in the study. One reviewer followed steps 1 to 3. Two
independent reviewers followed step 4 and selected studies. The inclusion or
exclusion of studies was decided unanimously. When there was disagreement, a
third reviewer made the final decision.</p></sec><sec><title>Data Items</title><p>The crude endpoints were stroke, death (any cause), major bleeding and atrial
fibrillation.</p></sec><sec><title>Data Collection Process</title><p>Two independent reviewers extracted the data. When there was disagreement about
data, a third reviewer checked the data and made the final decision. From each
study, we extracted patient characteristics, study design and outcomes.</p></sec><sec><title>Risk of Bias in Individual Studies</title><p>Included studies were assessed for the following characteristics: sequence
generation (randomization); allocation concealment (selection bias); blinding of
participants and personnel (performance bias); blinding of outcome assessors
(detection bias); incomplete outcome data addressed (attrition bias) and
selective outcome reporting (reporting bias). Taking these characteristics into
account, the papers were classified into A (low risk of bias), B (moderate risk
of bias) or C (high risk of bias). Two independent reviewers assessed risk of
bias. Agreement between the two reviewers was assessed with Kappa statistics for
full-text screening and rating of relevance and risk of bias. When there was
disagreement on risk of bias, a third reviewer checked the data and made the
final decision.</p></sec><sec><title>Summary Measures</title><p>The principal summary measures were RR with 95% confidence interval (CI) and
<italic>P</italic> values (considered statistically significant when<italic>
P</italic>&#x0003c;0.05) for stroke, death, major bleeding and atrial
fibrillation. The meta-analysis was completed with the Comprehensive
Meta-Analysis software (version 2, Biostat, Inc., Englewood, NJ, USA).</p></sec><sec><title>Synthesis of Results</title><p>Forest plots were generated for graphical presentations of clinical outcomes, and
we performed the I<sup>2</sup> test and &#x003c7;<sup>2</sup> test for the
assessment of heterogeneity across the studies<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Inter-study heterogeneity was explored using
the &#x003c7;<sup>2</sup> statistic, but the I<sup>2</sup>-value was calculated
to quantify the degree of heterogeneity across the studies that could not be
attributable to chance alone. When I<sup>2</sup> was more than 50%, significant
statistical heterogeneity was considered to be present. Each study was
summarized by the difference in means or RR, depending on the analyzed outcome.
The RR and the differences in means were combined across studies using a
weighted DerSimonian&#x02013;Laird random effects model<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p></sec><sec><title>Risk of Bias Across Studies </title><p>To assess publication bias, a funnel plot was generated for each outcome,
statistically assessed by Begg and Mazumdar's test<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> and Egger's test<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p></sec><sec><title>Sensitivity Analysis</title><p>We analyzed the pool data regarding the outcome &#x0201c;stroke&#x0201d; according to the
presence (or absence) of atrial septal aneurysm.</p></sec><sec><title>Meta-Regression Analysis</title><p>Meta-regression analysis was performed to determine whether the effects of the
PFO closure were modulated by pre-specified factors. Meta-regression graphs
describe the effect of aspirin on the outcome (plotted on the y-axis) as a
function of a given factor (plotted as a mean or proportion of that factor on
the x-axis). Meta-regression coefficients show the estimated increase in log
risk ration (RR) per unit increase in the covariate. Since log RR &#x0003e; 0
corresponds to RR &#x0003e; 1 and log RR &#x0003c; 0 corresponds to RR &#x0003c; 1, a negative
coefficient would indicate that as a given factor increases, the RR decreases,
and vice versa.</p><p>The pre-determined modulating factors examined were: age (mean &#x02013; years), male
gender (%), hypertension (%), smoking (%), large shunt before the interventions,
atrial septal aneurysm and effective closure (freedom from large shunt after the
interventions).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study Selection</title><p>A total of 3,970 citations were identified, of which 10 studies were potentially
relevant and retrieved as full-text. Six<sup>[<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r23" ref-type="bibr">23</xref>]</sup> publications
fulfilled our eligibility criteria. Interobserver reliability of study relevance
was excellent (Kappa=0.82). Agreement for decisions related to study validity
was very good (Kappa=0.84). The search strategy can be seen in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow Diagram of Studies Included in Data Search.</p></caption><graphic xlink:href="rbccv-33-05-0511-g01"/></fig></p></sec><sec><title>Study Characteristics</title><p>A total of 3,560 patients (device closure: 1,889 patients; medical therapy: 1,671
patients) were included from studies published from 2012 to 2018. All the trials
were multicentric. Most studies consisted of patients whose mean or median age
was approximately on the fourth decade of life. The medical therapy in the
studies was not homogeneous, since different regimens were applied (aspirin,
clopidogrel, dipyridamole, combined regimens, etc). The same goes for the
devices used, being the CLOSE trial most noteworthy for applying various devices
(<xref rid="t1" ref-type="table">Table 1</xref>). The overall internal
validity was considered &#x0201c;low risk of bias&#x0201d; (<xref rid="t2" ref-type="table">Table 2</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of populations.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">DEFENSE-PFO (N=120)</th><th align="center" rowspan="1" colspan="1">CLOSE (N=473)</th><th align="center" rowspan="1" colspan="1">REDUCE&#x000a0; (N= 664)</th><th align="center" rowspan="1" colspan="1">PC&#x000a0; (N=414)</th><th align="center" rowspan="1" colspan="1">RESPECT (N=980)</th><th align="center" rowspan="1" colspan="1">CLOSURE&#x000a0; (N=909)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>% of data in meta-analysis</bold></td><td align="center" rowspan="1" colspan="1">3.3</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">18.7</td><td align="center" rowspan="1" colspan="1">11.6</td><td align="center" rowspan="1" colspan="1">27.5</td><td align="center" rowspan="1" colspan="1">25.5</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Demographic variables</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Age &#x000b1; SD, years</td><td align="center" rowspan="1" colspan="1">49.0&#x000b1;15.0</td><td align="center" rowspan="1" colspan="1">43.3&#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">45.1&#x000b1;9.45</td><td align="center" rowspan="1" colspan="1">44.5&#x000b1;10.2</td><td align="center" rowspan="1" colspan="1">45.4&#x000b1;9.8</td><td align="center" rowspan="1" colspan="1">45.5&#x000b1;10.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Male (%)</td><td align="center" rowspan="1" colspan="1">55.8</td><td align="center" rowspan="1" colspan="1">58.9</td><td align="center" rowspan="1" colspan="1">60.1</td><td align="center" rowspan="1" colspan="1">49.8</td><td align="center" rowspan="1" colspan="1">54.7</td><td align="center" rowspan="1" colspan="1">51.8</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Medical history variables</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Currently smoking (%)</td><td align="center" rowspan="1" colspan="1">21.7</td><td align="center" rowspan="1" colspan="1">28.9</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">23.9</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">15.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Coronary artery disease (%)</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Diabetes (%)</td><td align="center" rowspan="1" colspan="1">11.7</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">7.4</td><td align="center" rowspan="1" colspan="1">7.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Hypercholesterolemia (%)</td><td align="center" rowspan="1" colspan="1">35.8</td><td align="center" rowspan="1" colspan="1">13.9</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">27.1</td><td align="center" rowspan="1" colspan="1">39.5</td><td align="center" rowspan="1" colspan="1">44.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Hypertension (%)</td><td align="center" rowspan="1" colspan="1">32.5</td><td align="center" rowspan="1" colspan="1">10.7</td><td align="center" rowspan="1" colspan="1">25.6</td><td align="center" rowspan="1" colspan="1">25.8</td><td align="center" rowspan="1" colspan="1">31.4</td><td align="center" rowspan="1" colspan="1">31.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Migraine (%)</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">30.6</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="1" colspan="1">38.8</td><td align="center" rowspan="1" colspan="1">33.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Prior stroke/TIA (%)</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">37.4</td><td align="center" rowspan="1" colspan="1">18.6</td><td align="center" rowspan="1" colspan="1">12.5</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Echocardiographic variables</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Atrial septal aneurysm (%)</td><td align="center" rowspan="1" colspan="1">10.8</td><td align="center" rowspan="1" colspan="1">32.7</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">23.7</td><td align="center" rowspan="1" colspan="1">35.6</td><td align="center" rowspan="1" colspan="1">35.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Large shunt (%)</td><td align="center" rowspan="1" colspan="1">57.5</td><td align="center" rowspan="1" colspan="1">92.8</td><td align="center" rowspan="1" colspan="1">39.3</td><td align="center" rowspan="1" colspan="1">21.7</td><td align="center" rowspan="1" colspan="1">76.1</td><td align="center" rowspan="1" colspan="1">61.1</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Treatment variables</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Randomized to device closure(%)</td><td align="center" rowspan="1" colspan="1">50.0</td><td align="center" rowspan="1" colspan="1">50.3</td><td align="center" rowspan="1" colspan="1">66.4</td><td align="center" rowspan="1" colspan="1">49.3</td><td align="center" rowspan="1" colspan="1">50.9</td><td align="center" rowspan="1" colspan="1">49.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Treated with medical therapy (%)</td><td align="center" rowspan="1" colspan="1">50.0</td><td align="center" rowspan="1" colspan="1">49.6</td><td align="center" rowspan="1" colspan="1">33.6</td><td align="center" rowspan="1" colspan="1">80.0</td><td align="center" rowspan="1" colspan="1">88.0</td><td align="center" rowspan="1" colspan="1">84.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Device</td><td align="center" rowspan="1" colspan="1">Amplatzer PFO Occluder (St. Jude Medical)</td><td align="center" rowspan="1" colspan="1">Amplatzer PFO Occluder or Cribriform; Starflex;
CardioSeal; Intrasept PFO; PFOStar; Helex; Premere; PFO occluder
OCCLUTECH; PFO occluder GORE (GSO)</td><td align="center" rowspan="1" colspan="1">EITHER the Helex Septal Occluder device OR the
Cardioform Septal Occluder</td><td align="center" rowspan="1" colspan="1">Amplatzer PFO Occluder (St. Jude Medical)</td><td align="center" rowspan="1" colspan="1">Amplatzer PFO Occluder (disc occluder)</td><td align="center" rowspan="1" colspan="1">STARFlex septal closure system (umbrella
occluder)</td></tr></tbody></table></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Analysis of Risk of Bias: Internal Validity.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Randomization</th><th align="center" rowspan="1" colspan="1">Selection bias</th><th align="center" rowspan="1" colspan="1">Performance bias</th><th align="center" rowspan="1" colspan="1">Detection bias</th><th align="center" rowspan="1" colspan="1">Attrition bias</th><th align="center" rowspan="1" colspan="1">Reporting bias</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DEFENSE-PFO</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">CLOSE 2017</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">REDUCE 2017</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">RESPECT 2013</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">PC 2013</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">CLOSURE I 2012</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">A</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>A=risk of bias is low; B=risk of bias is moderate; C=risk of bias is
high; D=incomplete reporting</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Synthesis of Results</title><p>The RR for stroke in the &#x0201c;device closure&#x0201d; group compared with the &#x0201c;medical
therapy&#x0201d; group in each study is reported in <xref ref-type="fig" rid="f2">Figure
2</xref>. There was evidence of moderate heterogeneity of treatment effect
among the studies for stroke. The overall RR (95% CI) of stroke showed a
statistically significant difference between the groups, favouring the &#x0201c;device
closure&#x0201d; group (random effect model: RR 0.366; 95%CI 0.171 &#x02013; 0.782,
<italic>P</italic>=0.010).</p><p><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Forest Plots of Efficacy Outcomes.</p></caption><graphic xlink:href="rbccv-33-05-0511-g02"/></fig></p><p>The RR for death in the &#x0201c;device closure&#x0201d; group compared with the &#x0201c;medical
therapy&#x0201d; group in each study is reported in <xref ref-type="fig" rid="f3">Figure
3A</xref>. There was no evidence of heterogeneity of treatment effect among
the studies for death. The overall RR (95% CI) of death showed no statistically
significant difference between the groups (random effect model: RR 0.781; 95%CI
0.331 &#x02013; 1.843, <italic>P</italic>=0.572).</p><p><fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Forest Plots of Safety Outcomes.</p></caption><graphic xlink:href="rbccv-33-05-0511-g03"/></fig></p><p>The RR for major bleeding in the &#x0201c;device closure&#x0201d; group compared with the
&#x0201c;medical therapy&#x0201d; group in each study is reported in <xref ref-type="fig" rid="f3">Figure 3B</xref>. There was evidence of mild heterogeneity of
treatment effect among the studies for major bleeding. The overall RR (95% CI)
of major bleeding showed no statistically significant difference between the
groups (random effect model: RR 0.878; 95%CI 0.446 &#x02013; 1.727,
<italic>P</italic>=0.706).</p><p>The RR for atrial fibrillation in the &#x0201c;device closure&#x0201d; group compared with the
&#x0201c;medical therapy&#x0201d; group in each study is reported in <xref ref-type="fig" rid="f3">Figure 3C</xref>. There was evidence of mild heterogeneity of
treatment effect among the studies for atrial fibrillation. The overall RR (95%
CI) of atrial fibrillation showed a statistically significant difference between
the groups (random effect model: RR 4.131; 95%CI 2.293 &#x02013; 7.443,
<italic>P</italic>&#x0003c;0.001).</p></sec><sec><title>Risk of Bias Across Studies</title><p>Funnel plot analysis (<xref ref-type="fig" rid="f4">Figure 4</xref>) disclosed no
asymmetry around the axis for the outcomes stroke, major bleeding and atrial
fibrillation, which means that we have low risk of publication bias related to
these outcomes. However, we detected a possibility of publication bias for the
outcome death.</p><p><fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Publication Bias Analysis of Clinical Outcomes by Funnel Plot
Graphic.</p></caption><graphic xlink:href="rbccv-33-05-0511-g04"/></fig></p></sec><sec><title>Sensitivity Analysis</title><p>Searching for evidence of a particular impact of the presence of an atrial septal
aneurysm on the results, we detected no difference between the groups (<xref ref-type="fig" rid="f5">Figure 5</xref>). Unfortunately, the REDUCE
trial<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> was left out
of this last analysis because the presence of an atrial septal aneurysm was
determined at the time of the PFO closure procedure and, therefore, it was not
recorded before trial entry or among the patients in the antiplatelet-only
group.</p><p><fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Sensitivity analysis for the presence of an atrial septal
aneurysm.</p></caption><graphic xlink:href="rbccv-33-05-0511-g05"/></fig></p></sec><sec><title>Meta-Regression Analysis</title><p>Meta-regression coefficients were statistically significant for the variables
hypertension, atrial septal aneurysm and effective closure regarding the outcome
&#x0201c;stroke&#x0201d;. For the variables hypertension and atrial septal aneurysm, we observed
that the larger the proportion of patients with hypertension and the larger the
proportion of patients with atrial septal aneurysm, the higher the risk for
stroke (<xref ref-type="fig" rid="f6">Figures 6A</xref>, <xref ref-type="fig" rid="f6">6B</xref>). Conversely, the larger the proportion of effective
closure, the lower the risk of stroke (<xref ref-type="fig" rid="f6">Figure
6C</xref>).</p><p><fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Meta-regression analysis.</p></caption><graphic xlink:href="rbccv-33-05-0511-g06"/></fig></p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec><title>Summary of Evidence</title><p>To our knowledge, this is the largest meta-analysis of studies performed to date
that provides incremental value by demonstrating that patients seem to benefit
from device closures in comparison to medical therapy in the reduction of the
rate of stroke. On the other hand, there was an increase in the rates of atrial
fibrillation. We did not identify the group of patients with an atrial septal
aneurysm as a particular group that benefits from the device closure in the
sensitivity analysis, although we identified this variable as a modulation
factor of the risk for stroke in the meta-regression. We also observed that the
benefit of the device closure in the reduction of the rates of stroke hinges on
the rate of effective closure. We did not find evidence that the publication of
the DEFENSE-PFO trial changed the scenario in the medical literature.</p></sec><sec><title>Some Comments</title><p>The lack of efficacy observed in the CLOSURE I trial has been put down to
ineffective PFO closure in the device arm, with 14% demonstrating significant
residual right-to-left shunting, whereas, in the other trials, we observed the
following rates: 3.3% (DEFENSE-PFO), 7% (CLOSE), 5.5% (REDUCE), 6.5% (RESPECT)
and 6.5% (PC trial). Our meta-regression showed that the more successful the
closure, the lower the risk of stroke in the device group (<xref ref-type="fig" rid="f6">Figure 6C</xref>). Therefore, we must bare in mind that &#x0201c;procedural
success&#x0201d;, which was defined in the studies as successful implantation with no
complications, does not mean &#x0201c;success of PFO closure&#x0201d;, which was defined in the
studies as minimal or no shunt after the procedure.</p></sec><sec><title>Risk of Bias and Limitations of the Present Study</title><p>There are inherent limitations with meta-analyses, including the use of
cumulative data from summary estimates. Patient data were gathered from
published data, not from individual patient follow-up. Access to individual
patient data would have enabled us to conduct further subgroup analysis and
propensity analysis to account for differences between the treatment groups.
This meta-analysis included only data from randomized studies, which do not
reflect the &#x0201c;real world&#x0201d; but, on the other hand, are less limited by publication
bias, treatment bias, confounders, and a certain tendency to overestimate
treatment effects observed in the observational studies, since patient selection
alters outcome and thus makes non-randomized studies less robust.</p><p>Moreover, besides statitiscal heterogeneity in some analyses, there is also the
issue of the clinical heterogeneity that might have played some role in the
pooled results. For instance, in the CLOSE trial, eleven different devices were
appplied for PFO closure. In the antiplatelet-only group and the PFO closure
group, 410 patients (86.7%) received aspirin, 51 (10.8%) received clopidogrel, 6
(1.3%) received aspirin with extended-release dipyridamole, and 6 (1.3%)
received aspirin with clopidogrel. As we can see, not all of patients were 100%
equally treated.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>This meta-analysis found that stroke rates are lower with percutaneously implanted
device closure than with medical therapy alone, being these rates modulated by the
rates of effective closure. The publication of the DEFENSE-PFO trial did not change
the current scenario.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MPBOS</td><td align="left" rowspan="1" colspan="1">Conception and design, analysis and interpretation of
data, drafting of the manuscript, revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">EESV</td><td align="left" rowspan="1" colspan="1">Collection of data, drafting of the manuscript,
revising it critically for important intellectual content; final
approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">LRPC</td><td align="left" rowspan="1" colspan="1">Collection of data, drafting of the manuscript,
revising it critically for important intellectual content; final
approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">RGSD</td><td align="left" rowspan="1" colspan="1">Revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">SCR</td><td align="left" rowspan="1" colspan="1">Revising it critically for important intellectual
content; final approval of the version to be published </td></tr><tr><td align="left" rowspan="1" colspan="1">AMM</td><td align="left" rowspan="1" colspan="1">Revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">RFAL</td><td align="left" rowspan="1" colspan="1">Revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">RCL</td><td align="left" rowspan="1" colspan="1">Revising it critically for important intellectual
content; final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="other"><p>This study was carried out at the Department of Cardiovascular Surgery, Pronto
Socorro Cardiol&#x000f3;gico de Pernambuco (PROCAPE), Recife, PE, Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kernan</surname><given-names>WN</given-names></name><name><surname>Ovbiagele</surname><given-names>B</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Bravata</surname><given-names>DM</given-names></name><name><surname>Chimowitz</surname><given-names>MI</given-names></name><name><surname>Ezekowitz</surname><given-names>MD</given-names></name><etal/><collab>American Heart Association Stroke Council</collab><collab>Council on Cardiovascular and Stroke Nursing</collab><collab>Council on Clinical Cardiology</collab><collab>Council on Peripheral Vascular Disease</collab></person-group><article-title>Guidelines for the prevention of stroke in patients with stroke
and transient ischemic attack: a guideline for healthcare professionals from
the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2014</year><volume>45</volume><issue>7</issue><fpage>2160</fpage><lpage>2236</lpage><pub-id pub-id-type="pmid">24788967</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>T</given-names></name><name><surname>Holmes</surname><given-names>AA</given-names></name><name><surname>Pahuja</surname><given-names>M</given-names></name><name><surname>Javed</surname><given-names>A</given-names></name><name><surname>Briasoulis</surname><given-names>A</given-names></name><name><surname>Telila</surname><given-names>T</given-names></name><etal/></person-group><article-title>Meta-analysis comparing patent foramen ovale closure versus
medical therapy to prevent recurrent cryptogenic stroke</article-title><source>Am J Cardiol</source><year>2018</year><volume>121</volume><issue>5</issue><fpage>649</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">29306484</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>S De</given-names></name><name><surname>Sievert</surname><given-names>H</given-names></name><name><surname>Sabatino</surname><given-names>J</given-names></name><name><surname>Polimeni</surname><given-names>A</given-names></name><name><surname>Sorrentino</surname><given-names>S</given-names></name><name><surname>Indolfi</surname><given-names>C</given-names></name></person-group><article-title>Percutaneous closure versus medical treatment in stroke patients
with patent foramen ovale: a systematic review and
meta-analysis</article-title><source>Ann Intern Med</source><year>2018</year><volume>168</volume><issue>5</issue><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">29310133</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Nayyar</surname><given-names>M</given-names></name><name><surname>Jovin</surname><given-names>IS</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name><name><surname>Bondy</surname><given-names>BR</given-names></name><name><surname>Fan</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Device closure versus medical therapy alone for patent foramen
ovale in patients with cryptogenic stroke: a systematic review and
meta-analysis</article-title><source>Ann Intern Med</source><year>2018</year><volume>168</volume><issue>5</issue><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">29310136</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntaios</surname><given-names>G</given-names></name><name><surname>Papavasileiou</surname><given-names>V</given-names></name><name><surname>Sagris</surname><given-names>D</given-names></name><name><surname>Makaritsis</surname><given-names>K</given-names></name><name><surname>Vemmos</surname><given-names>K</given-names></name><name><surname>Steiner</surname><given-names>T</given-names></name><etal/></person-group><article-title>Closure of patent foramen ovale versus medical therapy in
patients with cryptogenic stroke or transient ischemic attack: updated
systematic review and meta-analysis</article-title><source>Stroke</source><year>2018</year><volume>49</volume><issue>2</issue><fpage>412</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">29335335</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;</surname><given-names>MPBO</given-names></name><name><surname>Oliveira Neto</surname><given-names>LAP</given-names></name><name><surname>Nascimento</surname><given-names>GCSD</given-names></name><name><surname>Vieira</surname><given-names>EEDS</given-names></name><name><surname>Martins</surname><given-names>GL</given-names></name><name><surname>Rodrigues</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Closure of patent foramen ovale versus medical therapy after
cryptogenic stroke: meta-analysis of five randomized controlled trials with
3440 patients</article-title><source>Braz J Cardiovasc Surg</source><year>2018</year><volume>33</volume><issue>1</issue><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">29617507</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riaz</surname><given-names>H</given-names></name><name><surname>Khan</surname><given-names>MS</given-names></name><name><surname>Schenone</surname><given-names>AL</given-names></name><name><surname>Waheed</surname><given-names>AA</given-names></name><name><surname>Khan</surname><given-names>AR</given-names></name><name><surname>Krasuski</surname><given-names>RA</given-names></name></person-group><article-title>Transcatheter closure of patent foramen ovale following
cryptogenic stroke: an updated meta-analysis of randomized controlled
trials</article-title><source>Am Heart J</source><year>2018</year><volume>199</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">29754665</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelaziz</surname><given-names>HK</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>Abuomara</surname><given-names>HZ</given-names></name><name><surname>Nairooz</surname><given-names>R</given-names></name><name><surname>Pothineni</surname><given-names>NVK</given-names></name><name><surname>Madmani</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Long-term outcomes of patent foramen ovale closure or medical
therapy after cryptogenic stroke: a meta-analysis of randomized
trials</article-title><source>Catheter Cardiovasc Interv</source><year>2018</year><pub-id pub-id-type="doi">10.1002/ccd.27636</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smer</surname><given-names>A</given-names></name><name><surname>Salih</surname><given-names>M</given-names></name><name><surname>Mahfood Haddad</surname><given-names>T</given-names></name><name><surname>Guddeti</surname><given-names>R</given-names></name><name><surname>Saadi</surname><given-names>A</given-names></name><name><surname>Saurav</surname><given-names>A</given-names></name><etal/></person-group><article-title>Meta-analysis of randomized controlled trials on patent foramen
ovale closure versus medical therapy for secondary prevention of cryptogenic
stroke</article-title><source>Am J Cardiol</source><year>2018</year><volume>121</volume><issue>11</issue><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">29680170</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akobeng</surname><given-names>AK</given-names></name><name><surname>Abdelgadir</surname><given-names>I</given-names></name><name><surname>Boudjemline</surname><given-names>Y</given-names></name><name><surname>Hijazi</surname><given-names>ZM</given-names></name></person-group><article-title>Patent foramen ovale (PFO) closure versus medical therapy for
prevention of recurrent stroke in patients with prior cryptogenic stroke: a
systematic review and meta-analysis of randomized controlled
trials</article-title><source>Catheter Cardiovasc Interv</source><year>2018</year><pub-id pub-id-type="doi">10.1002/ccd.27615</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>Y</given-names></name><name><surname>Howard</surname><given-names>JP</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>MS</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Petraco</surname><given-names>R</given-names></name><etal/></person-group><article-title>Patent foramen ovale closure vs. medical therapy for cryptogenic
stroke: a meta-analysis of randomized controlled trials</article-title><source>Eur Heart J</source><year>2018</year><volume>39</volume><issue>18</issue><fpage>1638</fpage><lpage>1649</lpage><pub-id pub-id-type="pmid">29590333</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolo</surname><given-names>R</given-names></name><name><surname>Franzone</surname><given-names>A</given-names></name><name><surname>Siontis</surname><given-names>GCM</given-names></name><name><surname>Stortecky</surname><given-names>S</given-names></name><name><surname>Pilgrim</surname><given-names>T</given-names></name><name><surname>Meier</surname><given-names>B</given-names></name><etal/></person-group><article-title>Patent foramen ovale closure vs. medical therapy for recurrent
stroke prevention: Evolution of treatment effect during
follow-up</article-title><source>Int J Cardiol</source><year>2018</year><volume>255</volume><fpage>29</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">29338916</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>PRISMA Group</collab></person-group><article-title>Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement</article-title><source>Ann Intern Med</source><year>2009</year><volume>151</volume><issue>4</issue><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">19622511</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12958120</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Kacker</surname><given-names>R</given-names></name></person-group><article-title>Random-effects model for meta-analysis of clinical trials: an
update</article-title><source>Contemp Clin Trials</source><year>2007</year><volume>28</volume><issue>2</issue><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">16807131</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>CB</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name></person-group><article-title>Operating characteristics of a rank correlation test for
publication bias</article-title><source>Biometrics</source><year>1994</year><volume>50</volume><issue>4</issue><fpage>1088</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">7786990</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>G Davey</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical
test</article-title><source>BMJ</source><year>1997</year><volume>315</volume><issue>7109</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">9310563</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Song</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Heo</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Cryptogenic stroke and high-risk patent foramen ovale: the
DEFENSE-PFO trial</article-title><source>J Am Coll Cardiol</source><year>2018</year><volume>71</volume><issue>20</issue><fpage>2335</fpage><lpage>2342</lpage><pub-id pub-id-type="pmid">29544871</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mas</surname><given-names>JL</given-names></name><name><surname>Derumeaux</surname><given-names>G</given-names></name><name><surname>Guillon</surname><given-names>B</given-names></name><name><surname>Massardier</surname><given-names>E</given-names></name><name><surname>Hosseini</surname><given-names>H</given-names></name><name><surname>Mechtouff</surname><given-names>L</given-names></name><etal/><collab>CLOSE investigators</collab></person-group><article-title>Patent foramen ovale closure or anticoagulation vs. antiplatelets
after stroke</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><issue>11</issue><fpage>1011</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">28902593</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;ndergaard</surname><given-names>L</given-names></name><name><surname>Kasner</surname><given-names>SE</given-names></name><name><surname>Rhodes</surname><given-names>JF</given-names></name><name><surname>Andersen</surname><given-names>G</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Nielsen-Kudsk</surname><given-names>JE</given-names></name><etal/><collab>Gore REDUCE Clinical Study Investigators</collab></person-group><article-title>Patent foramen ovale closure or antiplatelet therapy for
cryptogenic stroke</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><issue>11</issue><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">28902580</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JD</given-names></name><name><surname>Saver</surname><given-names>JL</given-names></name><name><surname>Thaler</surname><given-names>DE</given-names></name><name><surname>Smalling</surname><given-names>RW</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>MacDonald</surname><given-names>LA</given-names></name><collab>RESPECT Investigators</collab><etal/></person-group><article-title>Closure of patent foramen ovale versus medical therapy after
cryptogenic stroke</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>12</issue><fpage>1092</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">23514286</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>B</given-names></name><name><surname>Kalesan</surname><given-names>B</given-names></name><name><surname>Mattle</surname><given-names>HP</given-names></name><name><surname>Khattab</surname><given-names>AA</given-names></name><name><surname>Hildick-Smith</surname><given-names>D</given-names></name><name><surname>Dudek</surname><given-names>D</given-names></name><etal/><collab>PC Trial Investigators</collab></person-group><article-title>Percutaneous closure of patent foramen ovale in cryptogenic
embolism</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>12</issue><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">23514285</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlan</surname><given-names>AJ</given-names></name><name><surname>Reisman</surname><given-names>M</given-names></name><name><surname>Massaro</surname><given-names>J</given-names></name><name><surname>Mauri</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>H</given-names></name><name><surname>Albers</surname><given-names>GW</given-names></name><etal/><collab>CLOSURE I Investigators</collab></person-group><article-title>Closure or medical therapy for cryptogenic stroke with patent
foramen ovale</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>11</issue><fpage>991</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">22417252</pub-id></element-citation></ref></ref-list></back></article>